Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Voxy

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Voxy head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 321 · Grade C

Voxy

Visit Voxy Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Voxy a bad call — it's best for readers comparing compounded injection plans who obtain the entire longer-term payment and cancellation calculation before selecting the lowest rate. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
36
Supply Reliability
95
79
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
75
Track Record
88
75
CoreAge RxBrief Score 94 · 63Voxy

Price, coverage & the tracker

CoreAge RxVoxy
Brief Score94/100 (A)63/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$175 billed monthly

Three-/six-/twelve-month options show $145/$120/$99 monthly equivalents, billed at the corresponding longer interval; full selected charge unconfirmed.

Provider, prescribed medication, supplies and shipping advertised included. No-fee cancellation does not establish an unused-prepaid refund.

Full price details

Compounded semaglutide injection offered; complete selected-plan quote unknown; $175 monthly, or $145/$120/$99 monthly equivalents billed every three/six/twelve months; full longer-term charges not established

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$225 billed monthly

Three-/six-/twelve-month options show $199/$175/$135 monthly equivalents, billed at the corresponding longer interval; full selected charge unconfirmed.

Confirm actual dose, quantity, shipment schedule and prepaid refund agreement before choosing the lowest equivalent.

Full price details

Compounded tirzepatide injection offered; complete selected-plan quote unknown; $225 monthly, or $199/$175/$135 monthly equivalents billed every three/six/twelve months; full longer-term charges not established

CoverageUS only; restrictions by state, confirmed at intakeNationwide service advertised, subject to clinician licensure and pharmacy authorization for the patient’s state
Brand-name accessNot confirmedBrand-name ingredient comparisons do not identify a current branded-prescription program.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Voxy: Monthly semaglutide/tirzepatide $175/$225; lower equivalents require three-, six- or twelve-month billing. Full selected charge, supply and unused-prepaid refund remain unconfirmed.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.